GlassScriptPhysician profile
David Alejandro Sanchez
NPI 1407346745
$12,911.34
in general payments reported to CMS, 2019-2025
11 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,372 · 2023: $11K · 2024: $349 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,087 · Consulting Fee: $4,744 · Food and Beverage: $1,312 · Honoraria: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,086.97 |
| Consulting Fee | $4,743.75 |
| Food and Beverage | $1,311.90 |
| Honoraria | $397.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,890.57 | 2022-2023 | |
| Grifols Shared Services North America, INC. | $5,591.09 | 2023 | |
| Dermavant Sciences, INC. | $368.68 | 2023-2024 | Vtama |
| Genzyme Corporation | $247.87 | 2023-2025 | |
| Genentech USA, INC. | $144.98 | 2024 | Xolair |
| Pharming Healthcare, INC. | $137.36 | 2023 | Ruconest |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Csl Behring | $124.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $122.20 | 2022 | |
| Blueprint Medicines Corporation | $109.36 | 2023 | |
| Merck Sharp & Dohme LLC | $49.65 | 2024-2025 | Gardasil 9, Gardasil, M-M-R II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.